In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Inspire Will Market AzaSite With 98-Rep Sales Force

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company announces agreement with InSite Vision to license bacterial conjunctivitis treatment pending at FDA with a late April user fee date.

You may also be interested in...



Inspire’s Ophthalmic Antibiotic AzaSite Gets FDA Nod

Firm highlights more convenient dosing of conjunctivitis treatment over currently available therapies.

Inspire’s Ophthalmic Antibiotic AzaSite Gets FDA Nod

Firm highlights more convenient dosing of conjunctivitis treatment over currently available therapies.

Inspire Will Use Allergy Expertise To Develop Phase III Antihistamine Compound

Inspire acquires the rights to FAES’ bilastine for the treatment or prevention of allergic rhinitis.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

Financing Quarterly Statistics, Q1 2024

Helping Organizations Deliver On KPIs And Giving Staff A Voice

Could Eledon’s Anti-CD40L Change Transplant Medicine?

See All
UsernamePublicRestriction

Register

PS065642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By